A B S T R A C T Autopsy findings suggest that lung surfactant is damaged in the adult respiratory distress syndrome. In the present study 225 bronchoalveolar lavage specimens (78 from 36 patients, 1-78 yr old with respiratory failure, 135 from another 128 patients with other respiratory disease, and 12 from healthy controls) were assayed for the lung profile [lecithin/ sphingomyelin (L/S) ratio, saturated lecithin, phosphatidylinositol, and phosphatidylglycerol]. Bronchoalveolar lavage fluid was further analyzed for phospholipids and for phosphatidic acid phosphohydrolase, phospholipase A2, and phosphatidylinositol phosphodiesterase activities. A lipid-protein complex was isolated and analyzed for surface activity, and plasma was measured for myoinositol.
and tended to normalize during recovery. Low L/S ratio (<2), and low phosphatidylglycerol (1% or less of glycerophospholipids) in bronchoalveolar lavage was always associated with respiratory failure. Abnormal lavage phospholipids were not due to plasma contamination. The phospholipase studies revealed little evidence of increased catabolism of phospholipids.
In respiratory failure, the lipid-protein complexes from lung lavage were not surface active, whereas that from healthy controls had surface properties similar to lung surfactant.
Phospholipids from patients with respiratory failure were similar to those from respiratory distress syndrome in the newborn. However, the latter condition is characterized by fast recovery of surfactant deficiency and by high plasma myoinositol that suppresses the synthesis of surfactant phosphatidylglycerol and increases phosphatidylinositol (Pediatr. Res. 1981. 15: 720.). On the other hand, in adult respiratory distress syndrome, the abnormality in surfactant phospholipids may last for weeks and in most cases is associated with low phosphatidylinositol, low phosphatidylglycerol, and low plasma myoinositol. INTRODUCTION Adult respiratory distress syndrome (ARDS),' acute respiratory failure with generalized lung involvement, carries a mortality rate of 50% or more despite recent advances in respiratory care (1) (2) (3) . Although ARDS is a heterogeneous syndrome associated with sepsis, aspiration, toxins, emboli, circulatory collapse, and metabolic, neurogenic, or hematologic disorders, among others, the resulting abnormalities in lung function are similar (4, 5) .
Ashbaugh et al. have suggested that the surfactant system is damaged in ARDS (6) . However, reports on surfactant in ARDS are scanty, and involve characterization of surface activity and phospholipids post mortem (7, 8 ) Although these studies demonstrate evidence of surfactant deficiency, it may be due to terminal or post-mortem changes and thus not represent mechanisms that lead to respiratory failure. In addition, there is evidence based upon animal studies, that the surfactant-producing type II alveolar cells are more resistant to acute alveolar injury than are other cells of the alveolocapillary unit, and that surfactant secretion may increase rather than decrease following lung injury (9, 10) . However, it is uncertain whether the mechanism and severity of lung damage in these model studies are similar to those in ARDS.
Respiratory distress syndrome of the newborn (RDS) bears similarities to ARDS both in symptoms and in radiologic findings. In RDS, a primary cause of the disease is a deficiency in surfactant. This is caused by immaturity in the alveolar epithelium resulting in deficient biosynthesis and secretion of surfactant (11) (12) (13) . Surfactant from developing fetal lung accumulates in amniotic fluid. It may be sampled, allowing evaluation of lung maturity. Postponing delivery until the surfactant system has matured prevents RDS. In addition, lung aspirates obtained during suctioning of airways can be analyzed for the biochemical diagnosis of RDS and for monitoring the recovery of the surfactant system (14, 15) .
Surfactant complex from normal adults contains, other than lecithins (-70% of total lecithin is disaturated, containing predominantly palmitate), phosphatidylglycerol in uniquely high concentration, phosphatidylethanolamine, phosphatidylinositol, cholesterol, small amounts of some other lipids, and, at the least one surfactant-specific protein that seems to possess phosphatidate phosphohydrolase activity (16) (17) (18) (19) . However, during fetal development, before the final maturation of the surfactant system, the complex contains no phosphatidylglycerol, but instead very high levels of phosphatidylinositol (15, 19) .
Owing to complexities in surfactant function and the possibility that a part rather than the whole complex is abnormal, it is preferable to monitor several surfactant components and to measure surface activity. The lung profile, which includes measurements of lecithin/sphingomyelin (L/S) ratio, saturated lecithin, phosphatidylglycerol, and phosphatidylinositol, is an accurate method of measuring lung maturity during the perinatal period (20) (21) .
In this study, we have characterized the biochemical and physicochemical properties of phospholipids recovered from bronchoalveolar lavage (BAL), and attempted to clarify mechanisms that lead to altered phospholipids in respiratory failure. The methods described allow monitoring of the peripheral airway lining during the course of ARDS.
METHODS

Study population
The number of patients and the number of specimens studied are shown in Table I . Subjects ranged in age from 1 to 78 yr: 117 were males, 59 females. Without knowledge of the biochemical analyses, patients were classified into diagnostic categories after review of the hospital record. These categories were defined as follows:
Respiratory failure. (a) Requirement for mechanical ventilation for more than 24 h, (b) requirement for 50% or more inspiratory oxygen, and (c) panlobar infiltrates on the Other' 14 27 Respiratory failure, no ARDSt 10 13 Pneumonia 19 22 Malignant tumor 15 16 Chronic obstructive pulmonary disease 19 19 Pulmonary alveolar proteinosis 5 5 Other respiratory disease § 70 73
Normal control 12 12 Total 176 225 chest radiographs (22 Other pulmonary disease. See Table I .
Normal controls. Seven subjects were nonsmoking adults, with normal arterial blood gases, physical examinations, and chest radiographs. In five others who underwent diagnostic bronchoscopy, the lung disease was considered to be inactive. BAL phospholipids (or the other analyses) from these five individuals were not significantly different from those from healthy volunteers.
Technique of obtaining BAL during bronchoscopy
Informed consent was obtained in each case before the procedure. The bronchoscope was wedged in a lower lobe segment (in most cases). 20 ml of normal saline was injected via the bronchoscope, and immediately suctioned into a Lukens trap attached directly to the bronchoscope. Among the children that were studied, 2-4 ml, instead of 20 ml of saline was used. In pulmonary alveolar proteinosis the specimens were obtained during therapeutic lavage.
Treatment of BAL
Half of each aspirate was available for the present study. BAL was centrifuged at 140 g for 5 min and the supernatant was used for analysis of lipids and enzymatic activities, unless otherwise indicated. The lipid-protein complex for the measurement of surface activity was isolated at 4°C as follows: BAL supernatant was centrifuged at 10,000 g for 2 h. The pellet was suspended in normal saline and layered on top of a discontinuous density gradient containing the following layers (4 ml 
Lipid analysis
The methods used have been described previously (20, 23) . Briefly, the lipids were extracted according to the method of Bligh and Dyer (24), followed by the diagnostic test, the lung profile (20) . Surface active phospholipids were concentrated by precipitation with cold acetone. The acetone precipitable and acetone soluble fractions were analyzed for phospholipids by two-dimensional thin-layer chromatography, the quantity of individual phospholipids was analyzed by reflect'ance densitometry (20) . Whenever sufficient amounts of lipids were available, the acetone precipitable and acetone soluble fractions were combined, and following analyses were performed: two-dimensional thin-layer chromatography of phospholipids that were quantified by measuring the phosphorus content of individual lipids (23) . Disaturated lecithin was analyzed according to Mason et al. (25) using OS04. The recovery of disaturated lecithin was calculated using [3H]dipalmitoyl lecithin (Applied Science Laboratories, State College, PA). Fatty acids of phosphatidylcholine were analyzed as methyl esters by gas-liquid chromatography (model 3920, Perkin-Elmer Corp., Norwalk, CT) as described previously (23) . The columns were packed with 10% Silar 10C on 100/120 mesh, and developed at 180°C using N2 as a carrier. The individual peaks were quantified by integrator (Hewlett-Packard Co., Palo Alto, CA).
Enzyme activities
For measurement of the enzyme activities, the BAL was used either fresh, or kept at -20°C for no longer than 2 wk. Storage did not significantly change the enzyme activities.
Phosphatidic acid phosphohydrolase (EC 3.1.3.4.) was assayed essentially as described by Johnston et al. (26) . The reaction mixture contained 0.2% Triton X-100, 0.1 M Trismaleate (pH 6.8), 0.4 mM [32P]phosphatidic acid, 19 ,000-32,000 cpm/assay, and 8-12 ug of BAL protein in 75 ul. The incubation with the radioactive isotope took place for 10 min, followed by lipid extraction and counting of the nonlipid layer for radioactivity. Blank activity was measured in the absence of BAL. Radioactive phosphatidic acid was prepared as follows: the membrane fraction derived from Escherichia coli (27) , heated for 5 min at 100°C, was incubated in the presence of 0.9 mM 1,2-dipalmitoyl-sn-glycerol, 0.5% cutscum, 40 mM sodium phosphate (pH 7.0), 0.4 mM aden-
Heights, IL), 50 mM MgSO4. Following incubation, the lipids were extracted (24) and radioactive phosphatidic acid was isolated using two-dimensional thin-layer chromatography. Phosphatidic acid carrier was purchased from Supelco Inc., Belefonte, PA.
Phospholipase A2 activity (EC 3.1.1.4) was measured in two different media. Each assay was run in duplicate. The incubation medium contained either 50 mM Tris-HCl, 0.1 mM EDTA, 10 mM CaCl2 (pH 8.0), or 50 mM Tris-maleate (pH 6.5). The reaction mixture additionally contained 5 X 104 cpm of [9,10-3H]2-palmitoyl L-a-dipalmitoyl lecithin (Applied Science), 0.5 mM L-a-dipalmitoyl lecithin, and 16-25 gg of BAL protein in 0.1 ml. Liposomes of lecithin were prepared by sonication in 0.5 M Tris-maleate or 0.5 M Tris-HCI. After incubation for 1 h at 370C, the reaction was terminated by extraction of the lipids. The lipid fraction, together with the palmitate carrier, was applied to silica gel H plates, and developed using petroleum ether/ethyl ether/ acetic acid (160:40:2 vol/vol/vol). The palmitate-containing lipid spot was counted for radioactivity. The amount of lecithin present in BAL was taken into account when the activity was calculated. Blank activity was measured in the absence of BAL.
Phosphatidylinositol phosphodiesterase (EC 3.1.4.10) activity was measured as follows: two duplicate assays in the presence of 0.5 mM [32P]phosphatidylinositol (7, 500 cpm/assay) and 5 mM Tris-maleate (pH 7.0) were perLung Surfactant Abnormality in Respiratory Failure 675 formed: one with 2 mM CaCl2, the other without CaCl2.
[82P]Phosphatidylinositol was suspended by sonication in 0.5 M Tris-maleate. BAL protein content was 16-25 tg in a final volume of 0.1 ml. After incubation at 370C for 20 min, the reaction was stopped by addition of chloroform (2 ml), and methanol (1 ml). Following the addition of 0.9 ml of 10 mM citrate (pH 2.0) the lipids were extracted according to Bligh and Dyer. The layer containing no lipid was counted for radioactivity, and the enzyme activity was calculated on the basis of the radioactivity released to the nonlipid layer minus the blank radioactivity with boiled BAL.
[12P]Phosphatidylinositol was prepared by incubating lung slices in Krebs-Ringer-bicarbonate medium containing 0.5 mM myoinositol and 10 mCi/ml of 32P-phosphate (23) .
[12P]Phosphatidylinositol was isolated by two-dimensional thin-layer chromatography followed by silicic acid column chromatography (28) . Carrier phosphatidylinositol was purchased from Supelco Inc.
Plasma myoinositol
This was measured as a trimethylsilyl ether derivative by gas-liquid chromatography (7620A research chromatograph with integrator, Hewlett-Packard Co.) using a-methylmannoside as an internal standard. 3 vol of 5% ZnSO4 and 3 vol of 0.3 N Ba(OH)2 were added to 1 vol of serum (50-100 ul), the mixture centrifuged at 900 g for 10 min and the supernatant freeze dried. 5 vol of the silylating mixture containing trimethylchlorosilane-hexamethyldisilazane-pyridine (1:3:9 vol/vol/vol, Sigma Chemical Co., St. Louis, MO) was added. After 60-90 min the mixture was evaporated under nitrogen, taken up in CS2, and analyzed on a 180-cm column of 3% SE-30 Supelcoport (80/100 mesh, Supelco Inc.).
Surface activity
The surface tension was measured in a Wilhelmy balance with a tight fitting Teflon barrier (29) . The maximum surface area was 444 cm2, and the minimum 40 cm2. The balance was housed within a double-walled thermostated (37±0.4°C) plastic bath. Air within the chamber was moistened with wet blotter pads. To avoid leaks at low surface tension, the inside walls of the trough were treated with LaCl3-disaturated lecithin mixture (29) . The complex containing 300 nmol phospholipid was applied to the surface in <30 ul of isopropanol/ water/chloroform (2:1:0.5 vol/vol/vol). 10 min after the application, the surface area was compressed, and then expanded at a constant rate of 5 cm2 X s-'. Surface tension vs. area isotherms were recorded using an X-Y recorder. There was no significant difference in the concentration of total phospholipid in BAL as compared amongst cases of ARDS, normal controls, chronic obstructive lung disease, pneumonia, and carcinoma (data not shown).
In six cases, two segments of the lung were lavaged (each with 20 ml of saline), during a single bronchoscopy, and the lavage returns were analyzed separately. Table II shows the measurements of the total phospholipid recovery, the concentration of total phospholipid, the L/S ratio and phosphatidylglycerol in these six cases. Furthermore, the difference between the lavage pairs are shown. The L/S ratio and phosphatidylglycerol revealed less difference between the pairs than either the total phospholipid (P < 0.02) or the total phospholipid concentration (P < 0.05).
Quality of phospholipids. Table III illustrates the lung profile from BAL. The specimens are divided into three groups: respiratory failure, normal controls, and other lung disease. In respiratory failure the phospholipids were strikingly different from the two other groups, particularly the L/S ratio and phosphatidylglycerol, which were low. Fig. 1 illustrates the lung profile from respiratory failure at the height of the disease and from normal controls. The regression lines included in the figure represent the sequential changes in the lung effluent phospholipids that take place during the last 3 mo of fetal development (20) . In respiratory failure, BAL phospholipids revealed similarities to phospholipids from immature lung, except for phosphatidylinositol, which was inappropriately low. In five cases phosphatidylglycerol was detectable (i.e., >1% of phospholipids). However, the phospholipids of lung effluent from healthy controls resembled those recovered from fetuses at term.
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M. Hallman, R. Spragg, J. H. Harrell, K. M. Moser, and L. Gluck The L/S ratio and phosphatidylglycerol during the course of ARDS. Fig. 2 shows data on the L/S ratio and phosphatidylglycerol in relation to the onset of respiratory failure. The indexes were abnormal early in the disease. In addition, there was evidence of normalization of the phospholipids during recovery.
Comparison between BAL and plasma lipids in ARDS. Considering the increased permeability of the alveolocapillary membrane, it is likely that plasma lipids contaminate BAL in ARDS. In five instances BAL and plasma lipids from ARDS were compared. Although the total L/S ratios were similar, and phosphatidylglycerol was undetectable in both plasma and BAL, several striking differences were detected: (a) disaturated lecithin/total lecithin ratio (BAL 0.29±0.08; serum 0.04±0.01); (b) phosphatidylserine (BAL 11.5±1.2% of total phospholipid; serum 1.2±0.6%); (c) glycolipid (BAL contains prominent glycolipid, while plasma has only traces of glycolipid, from normal subjects sedimented between 0.2 and 0.7 M sucrose. However, in respiratory failure most of the phospholipids were between 0.7 and 1.3 M sucrose. Table VIII , phosphatidate phosphohydrolase activity was lower in BAL from respiratory failure than in BAL from no respiratory failure. The result was significant even if the enzyme activity was expressed on the basis of the lavage phospholipids rather than the protein.
Considering the moderate increase in the lysolecithin fraction (Table IV) , and the low phosphatidylinositol (despite low phosphatidylglycerol) the phospholipases measured in BAL were phospholipase A2 and phosphatidylinositol phosphodiesterase. As shown in Table VIII , phospholipase A2 activity was low. When expressed on the basis of BAL protein, it tended to be lower in respiratory failure than in the other groups. However, when the activity was expressed on the basis of total phospholipid, the normal controls had lower activity than in other groups studied.
The activities of phosphatidylinositol phosphodiesterase were low, and frequently undetectable (data not shown).
Plasma myoinositol. The rationale of measuring plasma myoinositol was based on the following considerations: (a) in RDS high plasma myoinositol is associated with an absence of surfactant phosphatidylglycerol; (b) excess dietary myoinositol in adult rabbits prevents the synthesis of surfactant phosphatidylglycerol; and (c) phosphatidylglycerol was undetectable in most cases of ARDS.
Despite low or absent phosphatidylglycerol, plasma myoinositol was not significantly different as compared amongst ARDS (mean plasma myoinositol 29 ,uM, range 10-92, n = 20), and normal controls (35 ,uM, range 16-70, n = 8). However, in two cases of respiratory failure serum myoinositol was high (470 ;iM and 395 ,M), and BAL phosphatidylinositol prominent (14.4 and 17.0%). In these patients the respiratory failure was associated with renal and cardiac failure. The follow-up of the first case of respiratory failure revealed a normalization of plasma myoinositol (from 470 to 39 ,uM), appearance of phosphatidylglycerol, and concomitant alleviation of the respiratory symptoms. The other cases of respiratory failure (without ARDS) that were studied for plasma myoinositol did not differ from normal controls (myoinositol 37 Pneumonia (2 specimens), carcinoma (1 specimen), other lung disease (4 specimens).
I Pneumonia (3 specimens), carcinoma (2 specimens), other lung disease (2 specimens).
MM, range 17-94, n = 5). None of these cases had renal failure. DISCUSSION In ARDS the phospholipids recovered by lavaging the peripheral airways were frequently abnormal; namely the L/S ratio was low and phosphatidylglycerol undetectable. The disaturated lecithin was also frequently low, whereas sphingomyelin and phosphatidylserine were elevated as compared with these phospholipids recovered from healthy subjects or patients with various lung diseases without respiratory failure. These abnormalities tended to be present early in respiratory failure, regardless of the etiology, and to normalize during recovery. Furthermore, the lipidprotein complex from ARDS was not surface active, whereas in normal controls the lavage phospholipids resembled those in lung surfactant (cf. reference 31), and the lipid-protein complex was surface active. The present data are in accordance with previous evidence on analyses of lung lavage (7), or whole lung (8) at autopsy, and suggests that surfactant deficiency is important in the pathogenesis of ARDS and respiratory failure. In 20% of the specimens from ARDS the phospholipids did not strikingly differ from those in lung diseases without respiratory failure, but always differed from healthy controls. Besides the abnormal phospholipids, the surfactant complex may be functionally inactive owing to presence of factors that inhibit the function of surfactant complex (32, 33) . On the other hand, ARDS may be associated with different precipitating events (e.g., burns, vs. drowning), and therefore variations in surfactant damage; one insult may lead to deficiency in surfactant phospholipids, another to production of surfactant inhibitors. Although the present study did not reveal differences in BAL phospholipids as compared amongst the cases of respiratory failure with different precipitating events, this possibility remains to be studied further.
Surfactant phospholipids in the airways may be deficient because of a decreased rate of synthesis and secretion, or an increased rate of catabolism and/or clearance from the airways. Since the quantity of phospholipids recovered by BAL is not a reliable measure of surfactant, using the present technique of BAL, the quality of phospholipids was analyzed. Although qualitative analysis of surfactant phospholipids has proven to be a reliable method of measuring lung maturity during perinatal period, these measurements carry a disadvantage that additional phospholipids present in the airways could "dilute" the surfactant, even if surfactant secretion was not affected per se. Contaminating material also might be deleterious to surfactant function. Nonsurfactant lipids can originate from outside the lungs or from within the lung, including the type II alveolar cells.
Since increased permeability of the alveolar lining is widely recognized as an early alteration in lung damage (34, 35) (36) . In immature fetus and in RDS of the newborn, high extracellular (and apparently also type II cell) myoinositol seems to explain the absence of surfactant phosphatidylglycerol and prominent phosphatidylinositol (37) . It has additionally been suggested that absence of phosphatidylglycerol alters the surfactant function (19) .
Only in two cases of respiratory failure plasma myoinositol was excessively high (apparently caused by uremia, [38] ), phosphatidylglycerol absent, and phosphatidylinositol prominent. It is possible that in these cases myoinositol prevented phosphatidylglycerol synthesis, and therefore modified surfactant function. However, it is not known whether this was responsible for the respiratory failure, since the patients also had renal and cardiac failure. In the rest of the respiratory failure cases studied, both BAL phosphatidylinositol and plasma myoinositol were low (similar to healthy controls), and there was no evidence of increased breakdown of phosphatidylinositol. Therefore, the absence of phosphatidylglycerol likely was not due to high myoinositol (but to absence of surfactant), and although the phospholipids in lung effluent were similar in RDS and in ARDS, the pathobiochemistry seems different. RDS is basically a self-limiting, developmental disease, associated with high myoinositol and immature alveolar lining (37) . Characteristically, surfactant secretion surges within a few days of birth (15) . However, in ARDS, surfactant abnormality that is associated with low serum myoinositol may last for several weeks (Fig. 2) . Interestingly, alveolar damage induced by N-nitroso-N-methylurethane in adult animals is associated with surfactant abnormality that resembles the alteration of BAL phospholipids in ARDS. According to recent evidence, administration of excess myoinositol decreases N-nitroso-N-methylurethane-induced surfactant abnormality (except the absence of phosphatidylglycerol) (39) , and largely prevents the decrease in the number of type II alveolar cells (unpublished results).
The present findings are in agreement with the hypothesis that surfactant is deficient in respiratory failure, and that the abnormal lipid lining of the alveoli increases retractile forces, tends towards fluid accumulation, and decreases the compliance of the lung. Further investigation is required to elucidate the mechanism leading to surfactant deficiency, its prevention, and acceleration of recovery with drugs, diet, or by surfactant substitution.
